What is the half-life of PEG-MGF?

PEG-MGF has a half-life of Several hours (estimated 4-6 hours due to PEGylation), which is why it's typically administered 2-3 times per week, subcutaneous or intramuscular for optimal therapeutic effect.

How do I reconstitute PEG-MGF?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Muscle Growth

Preclinical

PEG-MGF

Also known as: PEGylated MGF, PEG MGF, PEG-Mechano Growth Factor

Overview

Key Facts

Primary Goal: A PEGylated (polyethylene glycol-conjugated) version of Mechano Growth Factor designed to overcome the extremely short half-life of native MGF

A PEGylated (polyethylene glycol-conjugated) version of Mechano Growth Factor designed to overcome the extremely short half-life of native MGF. The PEG moiety shields the peptide from rapid enzymatic degradation, extending its biological activity from minutes to several hours. This allows for systemic distribution and a more practical dosing protocol while retaining MGF's satellite cell-activating properties. Half-Life Several hours (estimated 4-6 hours due to PEGylation) Typical Dose 100–300 mcg Frequency 2-3 times per week, subcutaneous or intramuscular Cycle Length 4-6 weeks on, 2-4 weeks off

Dosing Information

Half-Life

Several hours (estimated 4-6 hours due to PEGylation)

Typical Dose

100–300 mcg

Frequency

2-3 times per week, subcutaneous or intramuscular

Cycle Length

4-6 weeks on, 2-4 weeks off

Administration Routes:

subcutaneousintramuscular

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Preclinical

PEG-MGF was developed to address the impractically short half-life of native MGF. Animal studies demonstrate that PEGylated MGF maintains satellite cell activation capacity while providing sustained plasma levels. Research shows significant improvements in muscle mass and strength in rodent models of muscle injury. No human clinical trials have been conducted, but the PEGylation strategy is well-established in pharmaceutical development (e.g., PEGfilgrastim, PEGinterferon).